model

Dynacure to Present Disease Progression Model and Natural History Study Data at the 25th Annual Congress of the World Muscle Society (WMS25)

STRASBOURG, Pa. and PHILADELPHIA, Sept. 28, 2020 /PRNewswire/ — Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that the company will present two posters containing data on the natural history of Myotubular and Centronuclear Myopathies (CNM) at the 25th Annual Congress of the World Muscle Society (WMS25). The WMS25 meeting is being held in a virtual format.

Dynacure is developing DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2), for the treatment of CNM. DYN101 is currently being evaluated in a Phase 1/2 clinical study, ‘UNITE-CNM’ (DYN101-C101), at multiple clinical sites in Europe.

Details of the poster presentations are listed below:

Poster Abstract: # LSP (late submitted poster) 6
Title: Hierarchical Bayesian model of disease progression in centronuclear myopathy allows to demonstrate treatment efficacy with a small sample size
Date: Thursday, October

Read More Read more